Recruiting studies: Diffuse Midline Glioma H3 K27 Altered

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of 177Lu-PSMA-617 in People With Gliomas
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07223034 ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
Phase 3 · 162 location(s) · Jazz Pharmaceuticals · NCT05580562 CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Phase 1/Phase 2 · 35 location(s) · Children's Oncology Group · NCT04870944 Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT07076498

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.